+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Trastuzumab Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030

  • PDF Icon

    Report

  • 175 Pages
  • September 2021
  • Region: Global
  • The Business Research Company
  • ID: 5446144
Trastuzumab Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global trastuzumab biosimilars market.







This report focuses on the trastuzumab biosimilars market which is experiencing strong growth. The report gives a guide to the trastuzumab biosimilars market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for trastuzumab biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Trastuzumab Biosimilars market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider trastuzumab biosimilars market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The trastuzumab biosimilars market section of the report gives context. It compares the trastuzumab biosimilars market with other segments of the trastuzumab biosimilars market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, trastuzumab biosimilars indicators comparison.

Scope


Markets Covered:


  • By Product: Ogivri; Herzuma; Ontruzant; Trazimera; Others
  • By Indication: Adjuvant Breast Cancer; Metastatic Breast Cancer; Metastatic Gastric Cancer; Others
  • By Distribution Channel: Hospital Pharmacy; Online Pharmacy

Companies Mentioned:


Amgen Inc.; Pfizer Inc; Samsung Bioepis; Merck & Co.; Biocon Limited

Countries:


Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions:


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series:


Five years historic and ten years forecast.

Data:


Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Trastuzumab Biosimilars Market

What is the estimated value of the Global Trastuzumab Biosimilars Market?

The Global Trastuzumab Biosimilars Market was estimated to be valued at $1.4 billion in 2021.

What is the growth rate of the Global Trastuzumab Biosimilars Market?

The growth rate of the Global Trastuzumab Biosimilars Market is 32.0%, with an estimated value of $4.25 billion by 2025.

What is the forecasted size of the Global Trastuzumab Biosimilars Market?

The Global Trastuzumab Biosimilars Market is estimated to be worth $4.25 billion by 2025.

Who are the key companies in the Global Trastuzumab Biosimilars Market?

Key companies in the Global Trastuzumab Biosimilars Market include Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion and EirGenix Inc.

Table of Contents

1. Executive Summary2. Trastuzumab Biosimilars Market Characteristics3. Trastuzumab Biosimilars Market Trends and Strategies4. Impact Of COVID-19 On Trastuzumab Biosimilars
5. Trastuzumab Biosimilars Market Size and Growth
5.1. Global Trastuzumab Biosimilars Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Trastuzumab Biosimilars Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Trastuzumab Biosimilars Market Segmentation
6.1. Global Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Ogivri
  • Herzuma
  • Ontruzant
  • Trazimera
  • Others
6.2. Global Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Adjuvant Breast Cancer
  • Metastatic Breast Cancer
  • Metastatic Gastric Cancer
  • Others
6.3. Global Trastuzumab Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy

7. Trastuzumab Biosimilars Market Regional and Country Analysis
7.1. Global Trastuzumab Biosimilars Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Trastuzumab Biosimilars Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Trastuzumab Biosimilars Market
8.1. Asia-Pacific Trastuzumab Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Trastuzumab Biosimilars Market
9.1. China Trastuzumab Biosimilars Market Overview
9.2. China Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Trastuzumab Biosimilars Market
10.1. India Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Trastuzumab Biosimilars Market
11.1. Japan Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Trastuzumab Biosimilars Market
12.1. Australia Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Trastuzumab Biosimilars Market
13.1. Indonesia Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Trastuzumab Biosimilars Market
14.1. South Korea Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Trastuzumab Biosimilars Market
15.1. Western Europe Trastuzumab Biosimilars Market Overview
15.2. Western Europe Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Trastuzumab Biosimilars Market
16.1. UK Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Trastuzumab Biosimilars Market
17.1. Germany Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Trastuzumab Biosimilars Market
18.4. France Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Trastuzumab Biosimilars Market
19.1. Eastern Europe Trastuzumab Biosimilars Market Overview
19.2. Eastern Europe Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Trastuzumab Biosimilars Market
20.1. Russia Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Trastuzumab Biosimilars Market
21.1. North America Trastuzumab Biosimilars Market Overview
21.2. North America Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Trastuzumab Biosimilars Market
22.1. USA Trastuzumab Biosimilars Market Overview
22.2. USA Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Trastuzumab Biosimilars Market
23.1. South America Trastuzumab Biosimilars Market Overview
23.2. South America Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Trastuzumab Biosimilars Market
24.1. Brazil Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Trastuzumab Biosimilars Market
25.1. Middle East Trastuzumab Biosimilars Market Overview
25.2. Middle East Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Trastuzumab Biosimilars Market
26.1. Africa Trastuzumab Biosimilars Market Overview
26.2. Africa Trastuzumab Biosimilars Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Trastuzumab Biosimilars Market, Segmentation by Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Trastuzumab Biosimilars Market Competitive Landscape and Company Profiles
27.1. Trastuzumab Biosimilars Market Competitive Landscape
27.2. Trastuzumab Biosimilars Market Company Profiles
27.2.1. Amgen Inc.
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Pfizer Inc
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Samsung Bioepis
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Merck & Co.
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Biocon Limited
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Trastuzumab Biosimilars Pipeline Analysis29. Key Mergers and Acquisitions in the Trastuzumab Biosimilars Market30. Trastuzumab Biosimilars Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright and Disclaimer

Executive Summary

Major players in the trastuzumab biosimilar market are Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd., and EirGenix, Inc.

The global trastuzumab biosimilars market is expected to grow from $1.22 billion in 2020 to $1.4 billion in 2021 at a compound annual growth rate (CAGR) of 14.8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.25 billion in 2025 at a CAGR of 32%.

The trastuzumab biosimilar market consists of the sales of trastuzumab biosimilar and related services by entities (organizations, sole traders, and partnerships) that manufacture trastuzumab biosimilar. Trastuzumab is a monoclonal antibody that interferes with human epidermal growth factor receptor (HER2). Trastuzumab biosimilars are used mainly for the treatment of breast cancer and gastroesophageal junction adenocarcinoma or metastatic gastric.

The trastuzumab biosimilar market covered in this report is segmented by product into ogivri, herzuma, ontruzant, trazimera, others. It is also segmented by indication into adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, others; by distribution channel into hospital pharmacy, online pharmacy.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The side effects of trastuzumab biosimilar are expected to limit the growth of the trastuzumab biosimilar market. The side effects of Herceptin (chemical name: Trastuzumab) include diarrhea, nausea, fever, heart problems, infection, cough, and rashes. Moreover, breast cancer studies reflect that the exposure of trastuzumab (Herceptin) therapy increased the rate of asymptomatic cardiac dysfunction in the two-year trastuzumab treatment from 4.6% to 8.1%. The rate of at least one patient experienced Grade-3 or higher, for treatment with trastuzumab is at 20.4% for two years, compared to 16.1% for one year of treatment. The side effects of trastuzumab have a negative impact on the trastuzumab biosimilar market.

In April 2019, Sandoz, a generic pharmaceutical company and a subsidiary of Novartis signed an agreement with EirGenix, Taiwan-based contract development and manufacturer, to market a proposed trastuzumab biosimilar for an undisclosed amount. The agreement gives rights to Sandoz to commercialize the trastuzumab biosimilar developed by EirGenix, available globally, excluding China and Taiwan. The terms included in the agreement are that the trastuzumab will be developed and manufactured by EirGenix while Sandoz will maintain the rights to the commercialization of the drug upon approval. This agreement is expected to keep in house resources of Sandoz focused on bringing robust internal pipeline products and expanding the existing portfolio of four oncology biosimilars.

The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilar market. Trastuzumab biosimilar is used in the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. According to the World Health Organization (WHO), in 2018, the new breast cancer cases registered were around 2.09 million, and stomach (gastric) cancer cases were around 1.03 million. According to Cancer India, breast cancer is the most common cancer in women in India and accounts for 14% of the cancers in women. Therefore, the rising prevalence of breast and gastric cancer increases the demand for trastuzumab biosimilar that helps save money when compared to expensive medicines, thereby driving the market.

Major players are continuously focusing on launching new products in the untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the trastuzumab biosimilars market are undergoing various strategic initiatives such as new product development, partnerships, geographical and product portfolio expansion to maintain their competitive position in the market and better serve the needs of the customers. For instance, in December 2019, Biocon and Mylan launched Ogivri (trastuzumab-dkst), Trastuzumab Biosimilar in the USA. Mylan plans to offer Ogivri in 150 mg and 420mg strengths, increase access for the treatment of HER2-positive breast and gastric cancer. In February 2020, Pfizer launched trastuzumab biosimilar to Herceptin, Trazimera in the USA. Trazimera is available for the treatment of human epidermal growth factor receptor 2 (HER2) metastatic gastric and breast cancer. Furthermore, in April 2020, Merck announced the launch of a Biosimilar of Herceptin (trastuzumab)- ONTRUZANT(trastuzumab-dttb). ONTRUZANT is available in the USA for approximately $1,325 and $3,709 for the 150 mg single-dose and 420 mg multiple-dose vial, respectively.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen Inc.
  • Pfizer Inc
  • Samsung Bioepis
  • Merck & Co.
  • Biocon Limited
  • Mylan Inc.
  • BioXpress Therapeutics
  • Celltrion
  • Teva Pharmaceutical Industries Ltd.
  • EirGenix Inc
  • ALTEOGEN Inc.
  • Apotex (Apobiologix)
  • AryoGen Pharmed
  • BIOCAD
  • Prestige BioPharma (PBP)
  • PlantForm
  • Outlook Therapeutics (Oncobiologics)
  • Shanghai CP Guojian Pharmaceutical
  • Shanghai Henlius Biotech
  • Stada Arzneimittel

Methodology

Loading
LOADING...